In the OSA setting, where surgery and chemotherapy remain the gold standard, the promising evaluation of anti-CSPG4 DNA vaccination in an adjuvant context following standard treatments [11] underscores the value of combining innovative approaches with established clinical protocols. This evidence concerns the gene CSPG4 and obstructive sleep apnea syndrome.